By the time the November 20th OHEAG date appeared on the MHRA calendar, the scientific review of DCVax-L had already been completed. The formal assessment occurred much earlier, in June 2024, when the MHRA routed the submission first to OHEAG and then immediately to the ATMP Technical Subcommittee. This subcommittee is the group responsible for evaluating advanced therapy medicinal products, including autologous cell vaccines. According to FOI 24/130, DCVax-L was formally referred there on June 25, 2024, which marks the point at which MHRA scientific review effectively ends. The agency does not return products to OHEAG a year later unless there are new data or safety issues. NWBO did not submit new clinical, statistical, or CMC data that would trigger a reassessment, confirming that the scientific component was not active in 2025.
What followed in 2024 and 2025 was administrative work, not clinical evaluation. Over that period, several system-level elements needed to be finalized around DCVax-L before a marketing authorization could be issued. The SI 87 modular manufacturing regulations, which establish the legal framework for decentralized and point-of-care manufacturing, came into force in early 2025. DCVax-L became the first therapy to apply for SI 87 Designation in July 2025, and the MHRA granted that status in September 2025. This was necessary to ensure the manufacturing model could be legally supported after approval. At the same time, Advent BioServices underwent a for-cause digital traceability inspection in September 2024. That audit focused on Flaskworks automation, electronic batch records, and data residency requirements, areas directly connected to the new SI 87 framework. Advent also received a pre-approval requirement from MHRA in June 2025 to construct a separate commercial Grade C manufacturing suite, segregated from clinical trial suites, which Advent publicly announced in late 2025.
The patient-facing components were also still being finalized. NWBO’s 2025 SEC filings confirm that the Patient Information Leaflet (PIL) underwent multiple rounds of revision, with MHRA requesting additional clarity on temperature control and administration instructions. In parallel, NICE placed DCVax-L into its joint MHRA–NICE review pilot, which allows health economic modeling to occur in real time with the regulatory review. NICE’s July 2025 minutes show DCVax-L on the “live tracking list,” an action NICE takes only after the MHRA confirms that the product has passed its major scientific hurdles.
Against this backdrop, the late-2025 OHEAG calendar entry takes on a different meaning. OHEAG’s November 20, 2025 meeting was part of the MHRA’s routine administrative decision cycle, a recurring period when the Licensing Authority aligns completed scientific assessments, finalizes internal documentation, and prepares for the issuance of marketing authorizations. There is no evidence that DCVax-L was reassessed scientifically on that date, nor would such a reassessment fit MHRA procedure. Instead, the date sits within the final administrative window where the MHRA prepares end-of-year decisions. This interpretation is consistent with the surrounding regulatory activity: all scientific and statistical questions had already been resolved, SI 87 designation had been granted, the commercial suite was underway, and NICE had already begun its parallel modeling.
The alignment between this administrative cycle and NWBO’s SEC filings is notable. The company filed its DEF 14A on November 28, 2025, a timing pattern that historically reflects a company being informed that a regulatory process has internally concluded. Companies do not file definitive proxy statements containing material updates unless they have certainty about the status of major ongoing regulatory matters. The one-week gap between the OHEAG administrative window and NWBO’s filing is consistent with the time typically required for the MHRA to complete internal notifications and for a company to prepare and submit its required shareholder materials.
Taken together, the timeline forms a coherent picture. The length of the review does not reflect uncertainty about DCVax-L’s evidence. The scientific review ended in mid-2024. Everything afterward involved integrating the therapy into SI 87, verifying manufacturing traceability, establishing a separated commercial suite, negotiating final labeling language, and coordinating with NICE under the parallel review model. These activities required administrative sequencing, not scientific debate. The November dates mark the end of that process and the point at which the decision moved from internal completion toward public issuance.
This interpretation is supported by MHRA workflow, NICE documentation, Advent inspection records, NWBO’s own filings, and the sequence of events surrounding SI 87. It represents the simplest and most internally consistent explanation of the timeline: DCVax-L’s scientific review was finished long before the end of 2025, and the final steps reflected system readiness rather than unresolved scientific questions.
Market Data 
Markets 
